Having trouble accessing articles? Reset your cache.

A new boost from sildenafil

Pfizer Inc.'s vasodilator sildenafil, marketed as Viagra for erectile dysfunction and as Revatio to treat pulmonary arterial hypertension, also could have utility in oncology, according to new findings by researchers at Virginia Commonwealth University. The team found that sildenafil has a unique synergy with doxorubicin: it not only reduces the chemotherapeutic's cardiotoxicity but also potentiates its efficacy.1

Doxorubicin is widely used in a host of cancers, but the drug's label includes a boxed warning of myocardial toxicity,

Read the full 766 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers